This activity is appropriate for:
House Officers, Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians

In the fields of:
Family Medicine, Gastroenterology, General Medicine, Hepatology, Internal Medicine, Primary Care, Transplant Surgery

 LEARNING OBJECTIVES

At the end of this activity, participant will understand and be able to implement:

• Latest developments in the management of nonalcoholic fatty liver disease (NAFLD) including insulin sensitizing agents
• Use of anti-craving agents and cognitive behavioral therapy in alcoholic liver disease (ALD) patients
• Information regarding the safety and efficacy of herbal products commonly used by patients with liver disease
• Up to date information on the role of albumin and terlipressin in the management of hepatorenal syndrome (HRS)
• Role of the microbiome and modern diagnostic approaches to hepatic encephalopathy
• Latest updates on proposed models to improve liver allocation in the US for liver transplant candidates

ACCREDITATION

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.